Aurobindo Pharma Stock Wobbles as USFDA Tags Key Facility with "Official Action Indicated" Status

Aurobindo Pharma Stock Wobbles as USFDA Tags Key Facility with "Official Action Indicated" Status​

Aurobindo Pharma shares are expected to remain under intense scrutiny following the disclosure that the United States Food and Drug Administration (USFDA) has designated its Eugia Unit-III formulation manufacturing facility as "Official Action Indicated" (OAI). This regulatory finding comes after a recent inspection conducted by US authorities, impacting the operational outlook for one of the company's key facilities.

The OAI classification signifies that observations were raised during the review process. The specific unit is operated by Eugia Pharma Specialities Ltd., a wholly owned subsidiary of Aurobindo Pharma and is located in Pashamylaram in Telangana.

USFDA Inspection Details and Regulatory Observations​

The USFDA conducted an inspection of the facility between January 27 and February 6, 2026. Following this review period, the regulator issued a total of 11 observations regarding the manufacturing process at the Eugia Unit-III site.

This classification adds to the complexities faced by the pharma giant as it navigates international regulatory requirements. The outcome means that the facility is now operating under specific conditions set forth by the US regulator.

Aurobindo Pharma Stock Performance and Valuation Metrics​

The company’s stock demonstrated resilience in the recent trading session, settling at Rs 1,472.25 in the previous trading session. This represented a gain of Rs 8.15 or 0.56 percent for the share.

Aurobindo maintains a robust market presence, with its current market capitalization standing at Rs 85,508.52 crore. The stock has shown strong appreciation over the past year, having gained more than 34 percent. It also continues to trade significantly above its five-year low mark.

Broader Company Developments and Milestones​

While facing regulatory hurdles, Aurobindo Pharma recently secured important milestones in the drug manufacturing space. Earlier this month, the company received final approval from the USFDA for Tofacitinib Tablets in 5 mg and 10 mg strengths.

Further strengthening its global capabilities, Aurobindo also inaugurated TheraNym, positioning itself as one of India's largest dedicated biologics contract manufacturing organisations (CMOs). The stock touched a 52-week high of Rs 1,550 on May 21, 2026.